Literature DB >> 21986821

Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.

Keunsook K Lee1, Donna M Maccallum, Mette D Jacobsen, Louise A Walker, Frank C Odds, Neil A R Gow, Carol A Munro.   

Abstract

Candida albicans cells with increased cell wall chitin have reduced echinocandin susceptibility in vitro. The aim of this study was to investigate whether C. albicans cells with elevated chitin levels have reduced echinocandin susceptibility in vivo. BALB/c mice were infected with C. albicans cells with normal chitin levels and compared to mice infected with high-chitin cells. Caspofungin therapy was initiated at 24 h postinfection. Mice infected with chitin-normal cells were successfully treated with caspofungin, as indicated by reduced kidney fungal burdens, reduced weight loss, and decreased C. albicans density in kidney lesions. In contrast, mice infected with high-chitin C. albicans cells were less susceptible to caspofungin, as they had higher kidney fungal burdens and greater weight loss during early infection. Cells recovered from mouse kidneys at 24 h postinfection with high-chitin cells had 1.6-fold higher chitin levels than cells from mice infected with chitin-normal cells and maintained a significantly reduced susceptibility to caspofungin when tested in vitro. At 48 h postinfection, caspofungin treatment induced a further increase in chitin content of C. albicans cells harvested from kidneys compared to saline treatment. Some of the recovered clones had acquired, at a low frequency, a point mutation in FKS1 resulting in a S645Y amino acid substitution, a mutation known to confer echinocandin resistance. This occurred even in cells that had not been exposed to caspofungin. Our results suggest that the efficacy of caspofungin against C. albicans was reduced in vivo due to either elevation of chitin levels in the cell wall or acquisition of FKS1 point mutations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21986821      PMCID: PMC3256049          DOI: 10.1128/AAC.00683-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  73 in total

1.  Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).

Authors:  Shawn A Messer; Ronald N Jones; Gary J Moet; Jeffrey T Kirby; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

2.  Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.

Authors:  Mette D Jacobsen; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

3.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Large-scale production of DNA sequencing templates by microtitre format PCR.

Authors:  A Rosenthal; O Coutelle; M Craxton
Journal:  Nucleic Acids Res       Date:  1993-01-11       Impact factor: 16.971

5.  Characterization of the chitin biosynthesis process as a compensatory mechanism in the fks1 mutant of Saccharomyces cerevisiae.

Authors:  L J García-Rodriguez; J A Trilla; C Castro; M H Valdivieso; A Durán; C Roncero
Journal:  FEBS Lett       Date:  2000-07-28       Impact factor: 4.124

6.  Exposure to caspofungin activates Cap and Hog pathways in Candida albicans.

Authors:  Judy Kelly; Raymond Rowan; Malachy McCann; Kevin Kavanagh
Journal:  Med Mycol       Date:  2009-11       Impact factor: 4.076

7.  A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase.

Authors:  C M Douglas; J A Marrinan; W Li; M B Kurtz
Journal:  J Bacteriol       Date:  1994-09       Impact factor: 3.490

8.  Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease.

Authors:  Leah E Cowen; Sheena D Singh; Julia R Köhler; Cathy Collins; Aimee K Zaas; Wiley A Schell; Hamza Aziz; Eleftherios Mylonakis; John R Perfect; Luke Whitesell; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

9.  The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans.

Authors:  Carol A Munro; Serena Selvaggini; Irene de Bruijn; Louise Walker; Megan D Lenardon; Bertus Gerssen; Sarah Milne; Alistair J P Brown; Neil A R Gow
Journal:  Mol Microbiol       Date:  2007-03       Impact factor: 3.501

10.  Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity.

Authors:  Armêl Plaine; Louise Walker; Gregory Da Costa; Héctor M Mora-Montes; Alastair McKinnon; Neil A R Gow; Claude Gaillardin; Carol A Munro; Mathias L Richard
Journal:  Fungal Genet Biol       Date:  2008-08-15       Impact factor: 3.495

View more
  77 in total

1.  Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis.

Authors:  Silvia Moretti; Silvia Bozza; Carmen D'Angelo; Andrea Casagrande; Maria Agnese Della Fazia; Lucia Pitzurra; Luigina Romani; Franco Aversa
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 2.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

Review 3.  Mechanisms of Antifungal Drug Resistance.

Authors:  Leah E Cowen; Dominique Sanglard; Susan J Howard; P David Rogers; David S Perlin
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

4.  Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility.

Authors:  M Martí-Carrizosa; F Sánchez-Reus; F March; E Cantón; P Coll
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

5.  Surface stress induces a conserved cell wall stress response in the pathogenic fungus Candida albicans.

Authors:  Clemens J Heilmann; Alice G Sorgo; Sepehr Mohammadi; Grazyna J Sosinska; Chris G de Koster; Stanley Brul; Leo J de Koning; Frans M Klis
Journal:  Eukaryot Cell       Date:  2012-12-14

Review 6.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 7.  Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Authors:  Danièle Maubon; Cécile Garnaud; Thierry Calandra; Dominique Sanglard; Muriel Cornet
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

8.  Modulation of Alternaria infectoria cell wall chitin and glucan synthesis by cell wall synthase inhibitors.

Authors:  Chantal Fernandes; Jorge Anjos; Louise A Walker; Branca M A Silva; Luísa Cortes; Marta Mota; Carol A Munro; Neil A R Gow; Teresa Gonçalves
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

9.  Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence.

Authors:  Cristina Rueda; Manuel Cuenca-Estrella; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

10.  Fungal cell wall dynamics and infection site microenvironments: signal integration and infection outcome.

Authors:  Kelly M Shepardson; Robert A Cramer
Journal:  Curr Opin Microbiol       Date:  2013-04-15       Impact factor: 7.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.